Month: August 2024

First Pacific Bank Announces Promotion of Tony DiVita to Executive Vice President, Chief Operating Officer

Written by Customer Service on August 13, 2024. Posted in Public Companies.

WHITTIER, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — First Pacific Bank, the wholly owned subsidiary of First Pacific Bancorp (OTC Pink: FPBC), is pleased to announce the promotion of Tony DiVita to Executive Vice President, Chief Operating Officer, effective immediately. In his new role, he will focus on driving operational efficiency and aligning our strategic goals to ensure we continue to deliver exceptional value to our customers. Tony DiVita, previously serving as Executive Vice President, Chief Banking Officer, has been a pivotal figure in the Bank’s success. His leadership, strategic vision, and unwavering commitment to the company’s mission and values have significantly contributed to the growth and stability of First Pacific Bank. “Tony has a wealth of experience and a proven track record of driving growth...

NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024

Written by Customer Service on August 13, 2024. Posted in Public Companies.

CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), for Blue Cross Blue Shield (BCBS) of Vermont Medical Members, effective 10/1/2024. This medical policy will bring our national total coverage for PENFS to roughly 23 million, with more decisions from major payers still pending. IB-Stim™ is a non-surgical device that sends gentle electrical impulses into cranial nerve bundles in the ear. NeurAxis’ PENFS technology is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents...

CPP Announces Acquisition and Rehabilitation of Sycamore Village Apartments in Pittsburg, Kansas

Written by Customer Service on August 13, 2024. Posted in Mergers And Acquisitions.

With the planned renovation, the 128-unit property’s affordability will be preserved until 2044 PITTSBURG, Kan., Aug. 13, 2024 (GLOBE NEWSWIRE) — CPP (Community Preservation Partners), a mission-driven affordable housing preservation developer, has announced the acquisition and planned renovation of Sycamore Village Apartments, an affordable housing community in southeast Kansas, near the Missouri border. CPP is partnering with Riverstone Platform Partners, LLC, a full-service real estate development and consulting company focusing on affordable, workforce, and market rate multifamily assets.Built in 1972, the 11-acre property was last renovated in 2006 and will undergo extensive improvements, creating a more enjoyable and family friendly environment for its residents. With a renovation cost of $188,924 per unit and a purchase...

CMUV Bancorp Announces 3rd Quarter 2024 Cash Dividend

Written by Customer Service on August 13, 2024. Posted in Dividend Reports And Estimates.

EL CENTRO, CA, Aug. 13, 2024 (GLOBE NEWSWIRE) — The Board of Directors of CMUV Bancorp, the bank holding company for Community Valley Bank, has approved a $0.12 3rd Quarter cash dividend per common share. The dividend will be payable on September 30, 2024, to all shareholders of record on September 6, 2024. Media Contact:Jon A EdneyPhone: 7603521889Email: mediarelations@yourcvb.com

Medical Imaging Market to Reach USD 60.0 Billion by 2031, Growing at 5.2% CAGR | SkyQuest Technology

Written by Customer Service on August 13, 2024. Posted in Mergers And Acquisitions.

Westford, USA, Aug. 13, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Medical Imaging Market will attain a value of USD 60.0 billion by 2031, with a CAGR of 5.2% during the forecast period (2024-2031). With the increasing prevalence of chronic cardiovascular diseases and the restructuring of health care systems, there has been an increased emphasis on early detection. The Centers for Disease Control and Prevention (CDC) estimates that coronary artery disease (CAD) affects 18.2 million adults each year in the United States. Diagnostic imaging uses various imaging techniques to obtain visual images of the body for diagnosis and treatment. This includes various forms of capturing images of the human body for diagnosis and treatment, and thus play an important role in improving overall health. 350 million tests are done for pediatric...

Studio City International Holdings Limited Announces Unaudited Second Quarter 2024 Earnings

Written by Customer Service on August 13, 2024. Posted in Earnings Releases And Operating Results.

MACAU, Aug. 13, 2024 (GLOBE NEWSWIRE) — Studio City International Holdings Limited (NYSE: MSC) (“Studio City” or the “Company”), a world-class integrated resort located in Cotai, Macau, today reported its unaudited financial results for the second quarter of 2024. Total operating revenues for the second quarter of 2024 were US$161.5 million, compared with total operating revenues of US$115.2 million in the second quarter of 2023. The increase was primarily attributable to the continued recovery in inbound tourism in Macau during the second quarter of 2024, and the ramp up of operations following the opening of Studio City Phase 2 in April 2023, which led to an increase in revenue from casino contract and higher non-gaming revenues. Studio City Casino generated gross gaming revenues of US$339.3 million and US$214.5 million for the...

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Written by Customer Service on August 13, 2024. Posted in Earnings Releases And Operating Results.

Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates Cash of $87.4 million as of June 30, 2024 expected to fund operations into 2027 LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the second quarter ended June 30, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $87.4 million as of June 30, 2024, which includes the net proceeds of the Company’s $50 million registered direct offering in June 2024. Mereo expects that this will provide cash...

Melco Announces Unaudited Second Quarter 2024 Earnings

Written by Customer Service on August 13, 2024. Posted in Earnings Releases And Operating Results.

MACAU, Aug. 13, 2024 (GLOBE NEWSWIRE) — Melco Resorts & Entertainment Limited (Nasdaq: MLCO) (“Melco” or the “Company”), a developer, owner, and operator of integrated resort facilities in Asia and Europe, today reported its unaudited financial results for the second quarter of 2024. Total operating revenues for the second quarter of 2024 were US$1.16 billion, representing an increase of approximately 22% from US$947.9 million for the comparable period in 2023. The increase in total operating revenues was primarily attributable to the improved performance in the mass market segment and non-gaming operations, led by the continued recovery in inbound tourism to Macau during the second quarter of 2024. Operating income for the second quarter of 2024 was US$123.7 million, compared with operating income of US$64.3 million in the...

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

Written by Customer Service on August 13, 2024. Posted in Earnings Releases And Operating Results.

GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million Achieved record-high prescription fills during Q2 75% year-over-year prescription fill increase; 32% growth compared to Q1 2024 Two abstracts submitted and accepted by the American College of Gastroenterology (ACG) focusing on use of GIMOTI in patients on GLP-1 analogs SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the second quarter ended June 30, 2024, and recent corporate developments. Matt D’Onofrio, CEO of Evoke Pharma, commented, “Exiting...

Kane Biotech Receives Funding Support to Expand the revyve™ Antimicrobial Wound Gel Family

Written by Customer Service on August 13, 2024. Posted in Public Companies.

WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and up to $200,000 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”). The funding will be received over a period of 20 months and will support the development of three additional products to build on Kane Biotech’s revyveTM Antimicrobial Wound Gel technology. The Company expects to be able to leverage its newly expanded US Food and Drug Administration (“FDA”) 510(k) clearance for its revyveTM Antimicrobial Wound Gel.(1) revyveTM Antimicrobial Wound Gel Spray: Will provide ease of use and is optimized for sensitive wounds like first-second degree burns and venous...

Month: August 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals